A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
Public ClinicalTrials.gov record NCT00546780. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) Plus Bortezomib Compared to Bortezomib Alone in Patients With Multiple Myeloma in First Relapse
Study identification
- NCT ID
- NCT00546780
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 31 participants
Conditions and interventions
Conditions
Interventions
- Bortezomib Drug
- Tanespimycin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2008
- Primary completion
- Feb 28, 2010
- Completion
- Feb 28, 2010
- Last update posted
- Jun 27, 2011
2008 – 2010
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Comprehensive Blood And Cancer Center | Bakersfield | California | 93309 | — |
| Moores Ucsd Cancer Center | La Jolla | California | 92093 | — |
| University Of California Medical Center | San Francisco | California | 94143 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| University Of Iowa Hospitals And Clinics | Iowa City | Iowa | 52242 | — |
| University Of Kansas Medical Center | Westwood | Kansas | 66205 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Henry Ford Health System Irb | Detroit | Michigan | 48202 | — |
| Capitol Comprehensive Cancer Care Center | Jefferson City | Missouri | 65109 | — |
| Columbia University Medical Center (Cumc) | New York | New York | 10032 | — |
| Wake Forest Univ Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| Kaiser Permanente Oncology/Hematology | Portland | Oregon | 97227 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37920 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| University Of Virginia Health System | Charlottesville | Virginia | 22908 | — |
| Medical College Of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00546780, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2011 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00546780 live on ClinicalTrials.gov.